# A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease

> **NCT05343364** · PHASE1 · COMPLETED · sponsor: **Phathom Pharmaceuticals, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Gastroesophageal Reflux

## Interventions

- **DRUG:** Vonoprazan

## Key facts

- **NCT ID:** NCT05343364
- **Lead sponsor:** Phathom Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-06-13
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05343364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05343364, "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05343364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*